Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP-IT RCT: HAIP Floxuridine + Systemic Therapy for Unresectable Colorectal Liver Metastases
NCT06857773Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine in colorectal cancer (CRC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Nov 2024; status: recruiting.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06857773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857773.